198 related articles for article (PubMed ID: 19093884)
1. Non-peptide macrocyclic histone deacetylase inhibitors.
Oyelere AK; Chen PC; Guerrant W; Mwakwari SC; Hood R; Zhang Y; Fan Y
J Med Chem; 2009 Jan; 52(2):456-68. PubMed ID: 19093884
[TBL] [Abstract][Full Text] [Related]
2. Macrocyclic histone deacetylase inhibitors.
Mwakwari SC; Patil V; Guerrant W; Oyelere AK
Curr Top Med Chem; 2010; 10(14):1423-40. PubMed ID: 20536416
[TBL] [Abstract][Full Text] [Related]
3. A structure-activity relationship of non-peptide macrocyclic histone deacetylase inhibitors and their anti-proliferative and anti-inflammatory activities.
Tapadar S; Fathi S; Raji I; Omesiete W; Kornacki JR; Mwakwari SC; Miyata M; Mitsutake K; Li JD; Mrksich M; Oyelere AK
Bioorg Med Chem; 2015 Dec; 23(24):7543-64. PubMed ID: 26585275
[TBL] [Abstract][Full Text] [Related]
4. Non-peptide macrocyclic histone deacetylase inhibitors derived from tricyclic ketolide skeleton.
Mwakwari SC; Guerrant W; Patil V; Khan SI; Tekwani BL; Gurard-Levin ZA; Mrksich M; Oyelere AK
J Med Chem; 2010 Aug; 53(16):6100-11. PubMed ID: 20669972
[TBL] [Abstract][Full Text] [Related]
5. Peptide based macrocycles: selective histone deacetylase inhibitors with antiproliferative activity.
Rajak H; Singh A; Dewangan PK; Patel V; Jain DK; Tiwari SK; Veerasamy R; Sharma PC
Curr Med Chem; 2013; 20(14):1887-903. PubMed ID: 23409715
[TBL] [Abstract][Full Text] [Related]
6. Progress in the Discovery of Macrocyclic Histone Deacetylase Inhibitors for the Treatment of Cancer.
Cheng K; Li S; Liao C
Curr Med Chem; 2017; 24(37):4166-4179. PubMed ID: 28183258
[TBL] [Abstract][Full Text] [Related]
7. Differential effects of class I isoform histone deacetylase depletion and enzymatic inhibition by belinostat or valproic acid in HeLa cells.
Dejligbjerg M; Grauslund M; Litman T; Collins L; Qian X; Jeffers M; Lichenstein H; Jensen PB; Sehested M
Mol Cancer; 2008 Sep; 7():70. PubMed ID: 18789133
[TBL] [Abstract][Full Text] [Related]
8. Natural and Synthetic Macrocyclic Inhibitors of the Histone Deacetylase Enzymes.
Maolanon AR; Kristensen HM; Leman LJ; Ghadiri MR; Olsen CA
Chembiochem; 2017 Jan; 18(1):5-49. PubMed ID: 27748555
[TBL] [Abstract][Full Text] [Related]
9. Non-natural macrocyclic inhibitors of histone deacetylases: design, synthesis, and activity.
Auzzas L; Larsson A; Matera R; Baraldi A; Deschênes-Simard B; Giannini G; Cabri W; Battistuzzi G; Gallo G; Ciacci A; Vesci L; Pisano C; Hanessian S
J Med Chem; 2010 Dec; 53(23):8387-99. PubMed ID: 21073160
[TBL] [Abstract][Full Text] [Related]
10. Novel amide derivatives as inhibitors of histone deacetylase: design, synthesis and SAR.
Andrianov V; Gailite V; Lola D; Loza E; Semenikhina V; Kalvinsh I; Finn P; Petersen KD; Ritchie JW; Khan N; Tumber A; Collins LS; Vadlamudi SM; Björkling F; Sehested M
Eur J Med Chem; 2009 Mar; 44(3):1067-85. PubMed ID: 18672316
[TBL] [Abstract][Full Text] [Related]
11. Chemical Editing of Macrocyclic Natural Products and Kinetic Profiling Reveal Slow, Tight-Binding Histone Deacetylase Inhibitors with Picomolar Affinities.
Kitir B; Maolanon AR; Ohm RG; Colaço AR; Fristrup P; Madsen AS; Olsen CA
Biochemistry; 2017 Sep; 56(38):5134-5146. PubMed ID: 28858522
[TBL] [Abstract][Full Text] [Related]
12. New pyrrole-based histone deacetylase inhibitors: binding mode, enzyme- and cell-based investigations.
Mai A; Valente S; Nebbioso A; Simeoni S; Ragno R; Massa S; Brosch G; De Bellis F; Manzo F; Altucci L
Int J Biochem Cell Biol; 2009 Jan; 41(1):235-47. PubMed ID: 18834955
[TBL] [Abstract][Full Text] [Related]
13. Prospects: histone deacetylase inhibitors.
Dokmanovic M; Marks PA
J Cell Biochem; 2005 Oct; 96(2):293-304. PubMed ID: 16088937
[TBL] [Abstract][Full Text] [Related]
14. Identification of histone deacetylase inhibitors with benzoylhydrazide scaffold that selectively inhibit class I histone deacetylases.
Wang Y; Stowe RL; Pinello CE; Tian G; Madoux F; Li D; Zhao LY; Li JL; Wang Y; Wang Y; Ma H; Hodder P; Roush WR; Liao D
Chem Biol; 2015 Feb; 22(2):273-84. PubMed ID: 25699604
[TBL] [Abstract][Full Text] [Related]
15. Chemical origins of isoform selectivity in histone deacetylase inhibitors.
Butler KV; Kozikowski AP
Curr Pharm Des; 2008; 14(6):505-28. PubMed ID: 18336297
[TBL] [Abstract][Full Text] [Related]
16. Pyrimethamine conjugated histone deacetylase inhibitors: Design, synthesis and evidence for triple negative breast cancer selective cytotoxicity.
Wu B; Fathi S; Mortley S; Mohiuddin M; Jang YC; Oyelere AK
Bioorg Med Chem; 2020 Mar; 28(6):115345. PubMed ID: 32061484
[TBL] [Abstract][Full Text] [Related]
17. Structure of 'linkerless' hydroxamic acid inhibitor-HDAC8 complex confirms the formation of an isoform-specific subpocket.
Tabackman AA; Frankson R; Marsan ES; Perry K; Cole KE
J Struct Biol; 2016 Sep; 195(3):373-378. PubMed ID: 27374062
[TBL] [Abstract][Full Text] [Related]
18. Histone deacetylase inhibitors: the Abbott experience.
Curtin M; Glaser K
Curr Med Chem; 2003 Nov; 10(22):2373-92. PubMed ID: 14529480
[TBL] [Abstract][Full Text] [Related]
19. The pharmaceutical potential of histone deacetylase inhibitors.
Elaut G; Rogiers V; Vanhaecke T
Curr Pharm Des; 2007; 13(25):2584-620. PubMed ID: 17897003
[TBL] [Abstract][Full Text] [Related]
20. Effects of novel HDAC inhibitors on urothelial carcinoma cells.
Kaletsch A; Pinkerneil M; Hoffmann MJ; Jaguva Vasudevan AA; Wang C; Hansen FK; Wiek C; Hanenberg H; Gertzen C; Gohlke H; Kassack MU; Kurz T; Schulz WA; Niegisch G
Clin Epigenetics; 2018 Jul; 10(1):100. PubMed ID: 30064501
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
